Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2011

View Archived Issues

AMP-224 boosts BCG-induced immune responses against bladder cancer

Preclinical activity of asthma candidate RV-1088 described at American Thoracic Society meeting

AlloStem Therapeutics designs novel MEK inhibitors

GlaxoSmithKline prepares new agents against hepatitis C virus

Phase I trials show AIC-316 is safe and well tolerated

Post hoc analysis supports selegiline transdermal system for treatment of depression

Wnt signaling inhibition has therapeutic activity in choroidal neovascularization

New anticancer antofine and cryptopleurine derivatives disclosed

Grindeks presents new agent for myocardial infarction

Phase II study begins for BKM-120 in recurrent glioblastoma

Gilead Sciences patents novel Toll-like receptor agonists

Ono Pharmaceutical recaps events of fourth quarter fiscal year 2011

ACADIA Pharmaceuticals receives NIH grant to develop new ER-beta agonists

BIBF-1120 moves to phase III in idiopathic pulmonary fibrosis

Oxford BioMedica presents update on drug pipeline

Ablynx discloses proof-of-concept phase II data on ozoralizumab in rheumatoid arthritis

Sprix analgesic nasal spray launched in U.S.

Merck & Co. and Roche enter into nonexclusive agreements for hepatitis C therapies

Histogenics acquires ProChon Biotech

CITN selects recombinant IL-7 CYT-107 for clinical testing at network institutions

Anacor initiates dosing in phase II trial of AN-2728 and AN-2898 in atopic dermatitis

ERYtech and Teva sign long-term agreement on Graspa

Quest Diagnostics acquires Celera

Shire to acquire Advanced BioHealing

CryoLife acquires Cardiogenesis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...